Market Cap (In KRW)
591.23 Billion
Revenue (In KRW)
9.48 Billion
Net Income (In KRW)
-14.49 Billion
Avg. Volume
396.52 Thousand
- Currency
- KRW
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 12650.0-26500.0
- PE
- -
- EPS
- -
- Beta Value
- 1.033
- ISIN
- KR7048410005
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Jong-Won Choi
- Employee Count
- -
- Website
- https://www.hyundaibioscience.com
- Ipo Date
- 2002-08-28
- Details
- Hyundai Bioscience Co., Ltd., a biotechnology company, develops and commercializes bio-fusion technology for delivering active ingredients to human body. The company provides Vitabrid C12, a new-conceptual vitamin C product that delivers active vitamin C into the skin. It also develops organic-inorganic hybrid technology, a drug delivery system technology that allows the selective and effective delivery of active substances on the target area in combination with bio-friendly minerals, as well as in anticancer drug carrier technology. The company was founded in 2000 and is based in Seoul, South Korea.
More Stocks
-
NGL-PCNGL Energy Partners LP
NGL-PC
-
UDAICEMENTUdaipur Cement Works Limited
UDAICEMENT
-
KMNCFKingsmen Creatives Ltd.
KMNCF
-
ASIMAR
-
601199
-
195870HAESUNG DS Co., Ltd.
195870
-
0989
-
005389Hyundai Motor Company
005389